Jasper Therapeutics (NASDAQ:JSPR) Announces Quarterly Earnings Results

Jasper Therapeutics (NASDAQ:JSPR) issued its quarterly earnings data on Thursday. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.17, FiscalAI reports.

Jasper Therapeutics Price Performance

Jasper Therapeutics stock traded down $0.07 during mid-day trading on Friday, reaching $0.79. 567,510 shares of the company were exchanged, compared to its average volume of 2,265,872. The firm has a market cap of $22.12 million, a PE ratio of -0.24 and a beta of 3.02. The company has a fifty day simple moving average of $0.59 and a 200-day simple moving average of $0.91. Jasper Therapeutics has a 12 month low of $0.32 and a 12 month high of $3.14.

Institutional Trading of Jasper Therapeutics

Several large investors have recently modified their holdings of the stock. Engineers Gate Manager LP bought a new stake in Jasper Therapeutics during the fourth quarter worth about $26,000. Panagora Asset Management Inc. bought a new position in Jasper Therapeutics in the 4th quarter valued at about $35,000. Acadian Asset Management LLC bought a new position in Jasper Therapeutics in the 1st quarter valued at about $46,000. Voleon Capital Management LP acquired a new position in shares of Jasper Therapeutics in the 3rd quarter valued at approximately $50,000. Finally, Jain Global LLC acquired a new position in shares of Jasper Therapeutics in the 4th quarter valued at approximately $79,000. 79.85% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Friday, July 17th. Wall Street Zen lowered Jasper Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Piper Sandler assumed coverage on Jasper Therapeutics in a report on Wednesday. They set an “overweight” rating and a $2.00 target price for the company. Royal Bank Of Canada set a $3.00 target price on shares of Jasper Therapeutics and gave the company a “sector perform” rating in a research report on Friday, May 15th. Finally, TD Cowen downgraded shares of Jasper Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th. Five equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $8.17.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.